

Corporate Medical Policy

Genetic Testing for Connective Tissue Disorders AHS – M2144

File Name: genetic_testing_for_connective_tissue_disorders
Origination: 01/2019
Last Review: 04/2022

Description of Procedure or Service

Definitions

More than 200 heritable connective tissue disorders exist and include Marfan Syndrome (MFS), Ehlers-Danlos syndrome (EDS), Epidermolysis bullosa (EB), and Loews-Dietz syndrome (LDS) (NIH, 2016). Every disorder impacts connective tissue differently, including several with vascular implications, and clinical severity varies within each disorder.

Related Policies

General Genetic Testing, Germline Disorders AHS – M2145

*****Note: This Medical Policy is complex and technical. For questions concerning the technical language and/or specific clinical indications for its use, please consult your physician.**

Policy

BCBSNC will provide coverage for genetic testing for connective tissue disorders when it is determined the medical criteria or reimbursement guidelines below are met.

Benefits Application

This medical policy relates only to the services or supplies described herein. Please refer to the Member's Benefit Booklet for availability of benefits. Member's benefits may vary according to benefit design; therefore member benefit language should be reviewed before applying the terms of this medical policy.

When Genetic Testing for Connective Tissue Disorder is covered

1. Genetic testing (FBN1 mutation) for Marfan syndrome is considered medically necessary (the individual needs to consult cardiology specialist prior to genetic testing) for any of the following indications
 - a. Marfan syndrome is suspected based on clinical features, but a definitive diagnosis cannot be made using established clinical diagnostic criteria (see Note 1 below)
 - b. Testing of an asymptomatic individual who has an affected first-degree blood relative (i.e., parent, sibling, child) with a known mutation.
 - c. The prenatal diagnosis or PGD of Marfan syndrome in the offspring of patients with known disease-causing variants.
2. Genetic testing for Loews-Dietz Syndrome (TGFBR1 or TGFBR2 mutation) is considered medically necessary for any of the following indications:

Genetic Testing for Connective Tissue Disorders AHS – M2144

- a. To confirm or establish a diagnosis of LDS in an individual with characteristics of LDS (see Note 2 below)
 - b. Testing of an asymptomatic individual who has an affected first-degree blood relative (i.e. parent, sibling, child) with a known mutation.
3. Genetic testing for COL3A1 and COL1A1 mutations to confirm or establish a diagnosis of vascular Ehlers-Danlos Syndrome (vEDS) is considered medically necessary in individuals with vascular characteristics of vEDS (see Note 3)
4. Panel multi-gene testing connective tissue disorders* (See Note 4) is considered medically necessary when individual displays signs and symptoms of a vascular connective tissue disorder including, but not limited to the following:
- a. Aneurysms/dissections
 - b. Pseudoaneurysms
 - c. Aortic root dilation and similar issues
 - d. Organ rupture
 - e. Pneumothorax

Note 1: Clinical Diagnostic Criteria for Marfan syndrome is as follows:

Revised Ghent nosology — The 2010 revised Ghent nosology puts greater weight on aortic root dilatation/dissection and ectopia lentis as the cardinal clinical features of MFS and on testing for mutations in *FBN1* (Loeys et al., 2010; Wright & Connolly, 2021).

- In the absence of family history of MFS, the presence of one of any of the following criteria is diagnostic for MFS:
 - Aortic criterion (aortic diameter $Z \geq 2$ or aortic root dissection) and ectopia lentis*
 - Aortic criterion (aortic diameter $Z \geq 2$ or aortic root dissection) and a causal *FBN1* mutation
 - Aortic criterion (aortic diameter $Z \geq 2$ or aortic root dissection) and a systemic score ≥ 7 points*
 - Ectopia lentis and a causal *FBN1* mutation that has been identified in an individual with aortic aneurysm
- In the presence of family history of MFS (as defined by the above criteria), the presence of one of any of the following criteria is diagnostic for MFS:
 - Ectopia lentis
 - Systemic score ≥ 7 points*
 - Aortic criterion (aortic diameter $Z \geq 2$ above 20 years old, $Z \geq 3$ below 20 years, or aortic root dissection) *

For criteria with an asterisk (*), the diagnosis of MFS can be made only in the absence of discriminating features of Shprintzen-Goldberg syndrome, Loeys-Dietz syndrome, or vascular Ehlers-Danlos syndrome **and** after *TGFBR1/2*, collagen biochemistry, or *COL3A1* testing if indicated.

- Systemic score — The revised Ghent nosology includes the following scoring system for systemic features (Loeys et al., 2010; Wright & Connolly, 2021): Wrist AND thumb sign: 3 points
- Wrist OR thumb sign: 1 point

Genetic Testing for Connective Tissue Disorders AHS – M2144

- Pectus carinatum deformity: 2 points
- Pectus excavatum or chest asymmetry: 1 point
- Hindfoot deformity: 2 points
- Plain pes planus: 1 point
- Pneumothorax: 2 points
- Dural ectasia: 2 points
- Protrusio acetabuli: 2 points
- Reduced upper segment/lower segment ratio AND increased arm span/height AND no severe scoliosis: 1 point
- Scoliosis or thoracolumbar kyphosis: 1 point
- Reduced elbow extension (≤ 170 degrees with full extension): 1 point
- Facial features (at least three of the following five features: dolichocephaly, malar hypoplasia, enophthalmos, downslanting palpebral fissures, retrognathia): 1 point
- Skin striae: 1 point
- Myopia >3 diopters: 1 point
- Mitral valve prolapse: 1 point

Note 2: Clinical features of Loeys-Dietz Syndrome: aortic/arterial aneurysms/tortuosity, arachnodactyly, bicuspid aortic valve and patent ductus arteriosus, blue sclerae, camptodactyly, cerebral, thoracic or abdominal arterial aneurysms and/or dissections, cleft palate/bifid uvula, club feet, craniosynostosis, easy bruising, joint hypermobility, ocular hypertelorism, pectus carinatum or pectus excavatum, scoliosis, talipes equinovarus, thin skin with atrophic scars, velvety and translucent skin, widely spaced eyes (Loeys & Dietz, 2018).

Note 3: Clinical features of Vascular EDS (vEDS) from The 2017 International Classification For The Ehlers-Danlos Syndromes (Malfait et al, 2017):

- Inheritance
Autosomal dominant
- Major criteria
 1. Family history of vEDS with documented causative variant in *COL3A1*
 2. Arterial rupture at a young age
 3. Spontaneous sigmoid colon perforation in the absence of known diverticular disease or other bowel pathology
 4. Uterine rupture during the third trimester in the absence of previous C-section and/or severe peripartum perineum tears
 5. Carotid-cavernous sinus fistula (CCSF) formation in the absence of trauma
- Minor criteria
 1. Bruising unrelated to identified trauma and/or in unusual sites such as cheeks and back
 2. Thin, translucent skin with increased venous visibility
 3. Characteristic facial appearance
 4. Spontaneous facial appearance
 5. Acrogeria
 6. Talipes equinovarus
 7. Congenital hip dislocation
 8. Hypermobility of small joints
 9. Tendon and muscle rupture
 10. Keratoconus
 11. Gingival recession and gingival fragility
 12. Early onset varicose veins (under age 30 and nulliparous if female)

Genetic Testing for Connective Tissue Disorders AHS – M2144

- Minimal criteria suggestive for vEDS:
A family history of the disorder, arterial rupture or dissection in individuals less than 40 years of age, unexplained sigmoid colon rupture, or spontaneous pneumothorax in the presence of other features consistent with vEDS should all lead to diagnostic studies to determine if the individual has vEDS. Testing for vEDS should also be considered in the presence of a combination of the other “minor” clinical features listed above.

Note 4: For 5 or more gene tests being run on the same platform, such as multi-gene panel next generation sequencing, please refer to AHS-R2162 Laboratory Procedures Medical Policy.

When Genetic Testing for Connective Tissue Disorder is not covered

Reimbursement is not allowed for all other panel gene testing for Marfan syndrome or other connective tissue disorders, including Ehlers-Danlos Syndrome.

Reimbursement is not allowed for genetic testing to confirm or establish a diagnosis of hypermobile Ehlers-Danlos syndrome (hEDS) in individuals with characteristics of hEDS (see Note 5).

Note 5: Clinical features of Hypermobile EDS (hEDS) from The 2017 International Classification For The Ehlers-Danlos Syndromes (Malfait et al, 2017):

- Inheritance
Autosomal dominant
- Molecular basis
Unknown
- Clinical diagnosis
clinical spectrum ranging from asymptomatic joint hypermobility, through “non-syndromic” hypermobility with secondary manifestations, to hEDS (see “A Framework for the Classification of Joint Hypermobility and Related Conditions” by Castori et al., this issue)
The clinical diagnosis of hEDS needs the simultaneous presence of criteria 1 AND 2 AND 3:

Criterion 1: Generalized Joint Hypermobility (GJH)

Criterion 2: Two or More Among the Following Features (A-C) MUST Be Present (for Example: A and B; A and C; B and C; A and B and C)

Feature A: systemic manifestations of a more generalized connective tissue disorder (a total of five must be present)

- 1.Unusually soft or velvety skin
- 2.Mild skin hyperextensibility
- 3.Unexplained striae such as striae distensae or rubrae at the back, groins, thighs, breasts and/or abdomen in adolescents, men or prepubertal women without a history of significant gain or loss of body fat or weight
- 4.Bilateral piezogenic papules of the heel
- 5.Recurrent or multiple abdominal hernia(s) (e.g., umbilical, inguinal, crural)
- 6.Atrophic scarring involving at least two sites and without the formation of truly papyraceous and/or hemosideric scars as seen in classical EDS
- 7.Pelvic floor, rectal, and/or uterine prolapse in children, men or nulliparous women without a history of morbid obesity or other known predisposing medical condition
- 8.Dental crowding and high or narrow palate
- 9.Arachnodactyly, as defined in one or more of the following: (i) positive wrist sign (Steinberg sign) on both sides; (ii) positive thumb sign (Walker sign) on both sides
- 10.Arm span-to-height ≥ 1.05

Genetic Testing for Connective Tissue Disorders AHS – M2144

- 11. Mitral valve prolapse (MVP) mild or greater based on strict echocardiographic criteria
- 12. Aortic root dilatation with Z-score > +2

Feature B: positive family history, with one or more first degree relatives independently meeting the current diagnostic criteria for hEDS.

Feature C: musculoskeletal complications (must have at least one)

- 1. Musculoskeletal pain in two or more limbs, recurring daily for at least 3 months
- 2. Chronic, widespread pain for ≥ 3 months
- 3. Recurrent joint dislocations or frank joint instability, in the absence of trauma (a or b)
 - a. Three or more atraumatic dislocations in the same joint or two or more atraumatic dislocations in two different joints occurring at different times
 - b. Medical confirmation of joint instability at two or more sites not related to trauma

Criterion 3: All the Following Prerequisites MUST Be Met

- 1. Absence of unusual skin fragility, which should prompt consideration of other types of EDS
- 2. Exclusion of other heritable and acquired connective tissue disorders, including autoimmune rheumatologic conditions. In patients with an acquired connective tissue disorder (e.g., lupus, rheumatoid arthritis, etc.), additional diagnosis of hEDS requires meeting both Features A and B of Criterion 2. Feature C of Criterion 2 (chronic pain and/or instability) cannot be counted towards a diagnosis of hEDS in this situation.
- 3. Exclusion of alternative diagnoses that may also include joint hypermobility by means of hypotonia and/or connective tissue laxity. Alternative diagnoses and diagnostic categories include, but are not limited to, neuromuscular disorders (e.g., myopathic EDS, Bethlem myopathy), other HCTD (e.g., other types of EDS, Loeys–Dietz syndrome, Marfan syndrome), and skeletal dysplasias (e.g., OI). Exclusion of these considerations may be based upon history, physical examination, and/or molecular genetic testing, as indicated.

Policy Guidelines

Table of Terminology

Term	Definition
AAP	American Academy of Pediatrics
AATS	American Association for Thoracic Surgery
ACC	American College of Cardiology
ACCF	American College of Cardiology Foundation
ACMG	American College of Medical Genetics
ACR	American College of Radiology
ACTA2	<i>Actin alpha 2, smooth muscle gene</i>
AD	Autosomal dominant
ADAMTS2	<i>ADAM metalloproteinase with thrombospondin type 1 motif 2 gene</i>
aEDS	Arthrochalasia Ehlers-Danlos syndrome
AHA	American Heart Association
AngII	Angiotensin II
AR	Autosomal recessive
ARBs	Angiotensin receptor blockers
ASA	American Stroke Association
ATR1	Angiotensin II receptor type 1

Genetic Testing for Connective Tissue Disorders AHS – M2144

<i>B3GALT6</i>	<i>Beta-1,3-galactosyltransferase 6 gene</i>
<i>B4GALT7</i>	<i>Beta-1,4-galactosyltransferase 7 gene</i>
BAV	Bicuspid aortic valve
BCS	Brittle cornea syndrome
C	Carboxy
C1R	Complement C1r
C1S	Complement C1s
CCS	Canadian Cardiovascular Society
CCSF	Carotid-cavernous sinus fistula
cEDS	Classical Ehlers-Danlos syndrome
<i>CHST14</i>	<i>Carbohydrate sulfotransferase 14 gene</i>
clEDS	Classical-like Ehlers-Danlos syndrome
CLIA '88	Clinical Laboratory Improvement Amendments Of 1988
CMS	Centers For Medicare and Medicaid Services
CNV	Copy number variant
<i>COL12A1</i>	<i>Collagen type XII alpha 1 chain gene</i>
<i>COL1A1</i>	<i>Collagen type I alpha 1 chain gene</i>
<i>COL1A2</i>	<i>Collagen type I alpha 2 chain gene</i>
<i>COL1A2 NMD</i>	<i>Collagen type I alpha 2 nonsense-mediated mRNA decay</i>
<i>COL3A1</i>	<i>Collagen type III alpha 1 chain gene</i>
CPD	Clinical provisional diagnosis
CT	Computerized tomography
cvEDS	Cardiac-valvular Ehlers-Danlos syndrome
CVS	Chorionic villus sampling
D4ST1	Dermatan 4-sulfotransferase-1 protein
dEDS	Dermatosparaxis Ehlers-Danlos syndrome
DNA	Deoxyribonucleic acid
DNMCC	Does not meet coverage criteria
<i>DSE</i>	<i>Dermatan sulfate epimerase gene</i>
EB	Epidermolysis bullosa
EDS	Ehlers-Danlos syndrome
EDS	Ehlers Danlos Society
<i>EFEMP2</i>	<i>EGF (epidermal growth factor) containing fibulin extracellular matrix protein 2 gene</i>
EGF	Epidermal growth factor
<i>ELN</i>	<i>Elastin gene</i>
EM	Electron microscopy
<i>FBN1</i>	<i>Fibrillin-1 gene</i>
<i>FBN2</i>	<i>Fibrillin-2 gene</i>
FDA	Food and Drug Administration
<i>FKBP14</i>	<i>FKBP (FK506 binding protein) prolyl isomerase 14 gene</i>
<i>FKBP22</i>	<i>FKBP (FK506 binding protein) prolyl isomerase 22 gene</i>
<i>FLNA</i>	<i>Filamin A gene</i>
GAG	Glycosaminoglycan
GJH	Generalized joint hypermobility
HCTD	Heritable connective tissue disorders
hEDS	Hypermobile Ehlers-Danlos syndrome
HP	Hydroxylysyl-pyridinoline

Genetic Testing for Connective Tissue Disorders AHS – M2144

HPLC	High-performance liquid chromatography
IFM	Immunofluorescence mapping
kEDS	Kyphoscoliotic
<i>KRT14</i>	<i>Keratin 14</i>
<i>KRT5</i>	<i>Keratin 5</i>
LDS	Loeys-Dietz syndrome
LDTs	Laboratory-developed tests
LH1	Lysyl hydroxylase 1
<i>LOX</i>	<i>Lysyl oxidase gene</i>
LP	Lysyl-pyridinoline
MCC	Meets coverage criteria
mcEDS	Musculocontractural Ehlers-Danlos syndrome
mEDS	Myopathic Ehlers-Danlos syndrome
MFS	Marfan syndrome
MLPA	Multiplex ligation-dependent probe amplification
MRI	Magnetic resonance imaging
MVP	Mitral valve prolapse
<i>MYH11</i>	<i>Myosin heavy chain 11 gene</i>
<i>MYLK</i>	<i>Myosin light chain kinase gene</i>
NGS	Next-generation sequencing
NORD	National Organization for Rare Disorders
OI	Osteogenesis imperfecta
PCR	Polymerase chain reaction
pEDS	Periodontal Ehlers-Danlos syndrome
PGD	Preimplantation genetic diagnosis
PGT-M	Preimplantation genetic testing for monogenic diseases
<i>PLEC</i>	<i>Plectin gene</i>
<i>PLOD1</i>	<i>Procollagen-Lysine,2-Oxoglutarate 5-Dioxygenase 1 gene</i>
<i>PRDM5</i>	<i>PR/SET Domain 5 gene</i>
<i>PRKG1</i>	<i>Protein kinase cGMP-dependent 1 gene</i>
RCT	Randomized controlled trial
RNA	Ribonucleic acid
SCA	Society of Cardiovascular Anesthesiologists
SCAI	Society for Cardiovascular Angiography and Interventions
SDS-PAGE	Sodium dodecyl sulphate–polyacrylamide gel electrophoresis
SIR	Society of Interventional Radiology
<i>SKI</i>	<i>SKI proto-oncogene</i>
<i>SLC2A10</i>	<i>Solute Carrier Family 2 Member 10 gene</i>
<i>SLC39A13</i>	<i>Solute Carrier Family 39 Member 13 gene</i>
<i>SMAD3</i>	<i>Mothers against decapentaplegic homolog 3</i>
<i>SMAD4</i>	<i>Mothers against decapentaplegic homolog 4</i>
SMC	Smooth muscle cell
spEDS	Spondylodysplastic Ehlers-Danlos syndrome
STS	Society of Thoracic Surgeons
SVM	Society for Vascular Medicine
TAD	Thoracic aortic disease
TEM	Transmission electron microscopy

Genetic Testing for Connective Tissue Disorders AHS – M2144

<i>TGFB</i>	<i>Transforming growth factor beta gene</i>
<i>TGFB2</i>	<i>Transforming Growth Factor B 2 Ligand gene</i>
<i>TGFB3</i>	<i>Transforming Growth Factor B 3 Ligand gene</i>
<i>TGFBR</i>	<i>Transforming growth factor beta receptor gene</i>
<i>TGFBR1</i>	Transforming Growth Factor B Receptor I
<i>TGFBR2</i>	Transforming Growth Factor B Receptor II
TGF-β	Transforming Growth Factor-B
<i>TNXA</i>	<i>Tenascin XA (Pseudogene)</i>
<i>TNXB</i>	<i>Tenascin XB gene</i>
vEDS	Vascular Ehlers-Danlos Syndrome
VUS	Variant of unknown significance
WES	Whole exome sequencing
WGS	Whole genome sequencing
ZIP13	Zrt- and Irt-like protein 13
<i>ZNF469</i>	<i>Zinc finger protein 469 gene</i>

Background

Connective tissue helps to bind and support other types of tissue in the body. Unfortunately, many types of connective tissue afflictions exist, including more than 200 heritable connective tissue disorders (NIH, 2016) such as Marfan Syndrome (MFS), Ehlers-Danlos syndrome (EDS), Epidermolysis bullosa (EB), and Loeys-Dietz syndrome (LDS). Each disorder affects connective tissue in a different manner. Symptoms may include joint issues, bone growth problems, blood vessel damage, cranial structural problems, skin problems, and height issues (NIH, 2016).

Marfan Syndrome (MFS) was first described more than 100 years ago by a Parisian professor of pediatrics, Antoine-Bernard Marfan. He was the first to report the association of long slender digits with other skeletal abnormalities in a 5-year-old girl (Radke & Baumgartner, 2014). MFS is a fairly common condition with an incidence of about 1 in 3000 to 5000 individuals. MFS is a systemic disorder of connective tissue with significant clinical variability across a broad phenotypic continuum, ranging from mild isolated features to severe and rapidly progressive neonatal multiorgan disease (Faivre et al., 2007). Ocular findings include myopia, ectopia lentis, and an increased risk for retinal detachment, glaucoma, and early cataracts. Skeletal system symptoms include “bone overgrowth and joint laxity, disproportionately long extremities for the size of the trunk, overgrowth of the ribs, and scoliosis.” The major cause of death in MFS results from cardiovascular system problems, including aortic root dilatation and rupture, mitral or tricuspid valve prolapse, and enlargement of the proximal pulmonary artery. Severe and prolonged regurgitation of the mitral or aortic valve can lead to left ventricular dysfunction and heart failure. Patients presenting with one isolated symptom are rare. However, with careful management, life expectancy approximates that of the general population (Dietz, 2017; Pyeritz, 2017; Wright & Connolly, 2021).

MFS primarily affects connective tissue, particularly the fibrillin component of the extracellular matrix. Fibrillins are large glycoproteins that form extracellular microfibrils that provide elasticity and structural support to tissues, modulate elastic fiber biogenesis and homeostasis, and regulate the bioavailability and activity of different growth factors (Davis & Summers, 2012; Grewal & Gittenberger-de Groot, 2018). Fibrillin-1 is an important matrix component of both elastic and nonelastic tissues (Wright & Connolly, 2021). Mutations can lead to impaired fibrillin-1 protein function, causing extracellular matrix integrity to fail (Grewal & Gittenberger-de Groot, 2018). These fibrillin-1 problems also cause smooth muscle cell (SMC) contractile dysfunction and dysregulation of the tensile strength of aortic tissue, which is a common finding in many cardiovascular

Genetic Testing for Connective Tissue Disorders AHS – M2144

conditions (Nataatmadja et al., 2003). Recent studies indicate a role for SMC phenotype in the pathogenesis of MFS. Early phenotypic switch resulting from *FBNI* mutation appears to be associated with initiation of important metabolic changes in SMCs that contribute to subsequent pathology (Dale et al., 2017). Mutation in *FBNI* has been shown to dysregulate the transforming growth factor- β (TGF- β) pathway, as matrix sequestration of cytokines is crucial to their regulated activation and signaling (Bin Mahmood et al., 2017; Neptune et al., 2003).

EDS is a term that encompasses several rare genetic connective tissue disorders. Each disorder is characterized by specific features, including “skin hyperextensibility, joint hypermobility, and tissue fragility,” and affects approximately 1 in 5000 individuals (Pauker & Stoler, 2020). EDS hypermobile type (hEDS) is the most common type of EDS. Unfortunately, the genetic basis for hEDS is still unknown, meaning that a genetic test to confirm diagnosis is not available for this subtype. As of 2017, an international forum has classified EDS into 13 different subtypes. The table below has been modified from Malfait et al. (2017) and lists all EDS types:

Clinical EDS Subtype	Abbreviation	Inheritance Pattern	Genetic Bases	Protein
Classical EDS	cEDS	AD (autosomal dominant)	Major: <i>COL5A1</i> , <i>COL5A1</i>	Type V collagen
			Rare: <i>COL1A1</i>	Type I collagen
Classical-like EDS	clEDS	AR (autosomal recessive)	<i>TNXB</i>	Tenascin XB
Cardiac-valvular	cvEDS	AR	<i>COL1A2</i> (biallelic mutations that lead to <i>COL1A2</i> NMD and absence of pro α 2(I) collagen chains)	Type I collagen
Vascular EDS	vEDS	AD	Major: <i>COL3A1</i>	Type III collagen
			Rare: <i>COL1A1</i>	Type I collagen
Hypermobile EDS	hEDS	AD	Unknown	Unknown
Arthrochalasia EDS	aEDS	AD	<i>COL1A1</i> , <i>COL1A2</i>	Type I collagen
Dermatosparaxis EDS	dEDS	AR	<i>ADAMTS2</i>	ADAMTS-2
Kyphoscoliotic EDS	kEDS	AR	<i>PLOD1</i>	LH1
			<i>FKBP14</i>	FKBP22
Brittle Cornea syndrome	BCS	AR	<i>ZNF469</i>	ZNF469
			<i>PRDM5</i>	PRDM5
Spondylodysplastic EDS	spEDS	AR	<i>B4GALT7</i>	β 4GalT7
			<i>B3GALT6</i>	β 3GalT6
			<i>SLC39A13</i>	ZIP13

Genetic Testing for Connective Tissue Disorders AHS – M2144

Musculocontractural EDS	mcEDS	AR	<i>CHST14</i> <i>DSE</i>	D4ST1 DSE
Myopathic EDS	mEDS	AD or AR	<i>COL12A1</i>	Type XII collagen
Periodontal EDS	pEDS	AD	<i>C1R</i> <i>C1S</i>	C1r C1s

This naming convention has also been adopted by The Ehlers Danlos Society (EDS, 2017), who previously used Villefranche nosology to classify EDS types. Unfortunately, no cure for EDS currently exists, and treatments may include physical therapy, braces, counseling, and pain medication (Pauker & Stoler, 2020).

Vascular EDS (vEDS) is characterized by “arterial aneurysm, dissection and rupture, bowel rupture, and rupture of the gravid uterus” and affects 1 in 50,000 to 200,000 individuals (Byers et al., 2017). These arterial aneurysms may be life threatening. As noted in the table above, this disorder is due to mutations in the *COL3A1* or *COL1A1* genes, with a sequence analysis of *COL3A1* thought to identify approximately 98% of vEDS cases (Malfait et al., 2017). A diagnosis depends on clinical features, including family history. Aneurysms occur in other types of EDS, including classical EDS (cEDS), due to vascular fragility (Malfait, 2018). Johansen et al. (2020) published a recent cross-sectional study with data collected from 18 patients with genetically verified vEDS and 34 patients with genetically verified LDS. The median age at diagnosis was 34 years. “Most respondents (87%) had cardiovascular surveillance visits, 58% yearly or more often, and still 29% had no antihypertensive medications (Johansen et al., 2020).”

LDS was first described in 2005 and is now considered an autosomal dominant connective tissue disorder characterized by “aortic aneurysms and generalized arterial tortuosity, hypertelorism, and bifid/broad uvula or cleft palate” (MacCarrick et al., 2014). LDS was initially characterized by mutations in the transforming growth factor β receptor I (*TGFBR1*) and transforming growth factor β receptor II (*TGFBR2*) genes; however, additional genes have been identified, including the mothers against decapentaplegic homolog 3 (*SMAD3*) gene, the transforming growth factor β 2 ligand (*TGFB2*) gene, and the transforming growth factor β 3 ligand (*TGFB3*) gene (MacCarrick et al., 2014; Wright & Connolly, 2021). If a mutation is identified in all three genes, transforming growth factor- β (TGF- β) signaling is affected and patients typically exhibit similar craniofacial, cutaneous, cardiovascular, and skeletal features. Vascular involvement in LDS has recently been studied by Jud and Hafner (2019) who published a case study which followed a woman with a history of ectasias of the aortic arch, abdominal aorta, carotid bulbs, and common femoral arteries, as well as an asymptomatic aneurysm in superior mesenteric artery. In comparing surgical outcomes between those with LDS versus MFS, it was found that LDS patients had a greater likelihood of reoperation for aortic arch aneurysms than MFS patients, and that those with mutations in *TGFBR1* had higher rates of reoperation than those with *TGFBR2* mutations (Seike et al., 2020).

Epidermolysis bullosa (EB) is a group of hereditary diseases characterized by mucosa and skin fragility due to mutations that affect skin structural proteins, causing the skin to easily blister. Four major types of EB have been identified and include EB simplex, junctional EB, dystrophic EB, and Kindler syndrome (Murrell, 2020). Unfortunately, there is currently no effective therapeutic option for this disorder, and treatment largely focuses on wound management. All of the major EB types may result from mutations in the keratin 5 (*KRT5*) or keratin 14 (*KRT14*) gene (Coulombe et al., 1991; NIH, 2020). These two genes work together to encourage strength in the epidermis. Mutations prevent the keratin from assembling in necessary networks, leading to fragility. Further, a rare type of EB, known as

Genetic Testing for Connective Tissue Disorders AHS – M2144

Ogna, has been associated with mutations in the *PLEC* gene, leading to issues in the attachment of the epidermis to other layers of the skin (NIH, 2020). Ryan et al. (2016) note that ventricular dysfunction and aortic dilation have been identified in patients with recessive dystrophic EB.

Clinical Validity and Utility

More than 90% of patients with the typical Marfan phenotype have mutations involving the gene encoding the connective tissue protein fibrillin-1 (*FBNI*). Out of a sample of 93 patients with MFS, 85 (91%) were found to have a *FBNI* mutation. The eight remaining patients did not display any drastically different clinical features or family history, and the authors suggest that *FBNI* mutations that go undetected are due to technical limitations (Loeys et al., 2004). Most patients have a family history of MFS, but up to 25% have a mutation *de novo*. Mutations are in one of five categories: nonsense, frameshift (deletion, insertion), splicing errors, a missense mutation that substitutes or creates cysteine residues, or a missense mutation affecting a conserved EGF sequence. Although the phenotypic variability is wide, mutations involving exon skipping tend to result in more severe disease. Genetic findings have importance in the diagnosis, risk stratification, and clinical management of patients, as well as identifying potentially affected relatives (Wright & Connolly, 2021).

Becerra-Munoz et al. (2018) conducted a prospective cohort study to summarize variants in *FBNI* and establish a genotype-phenotype correlation. Genotype-phenotype correlations have identified that patients with MFS and truncating variants in *FBNI* presented a higher proportion of aortic events compared to a more benign course in patients with missense mutations. A total of 84 patients fulfilled the Ghent diagnostic criteria, and of these 84, 44 had missense mutations and 35 had truncating mutations. However, of the 44 with missense mutations, only six had suffered an aortic event (such as aortic aneurysm) whereas 20 of the 35 with a truncating mutation had suffered an aortic event (Becerra-Munoz et al., 2018). Up to 10% of patients with the Marfan phenotype have no identifiable mutation in the *FBNI* gene. Rather, mutations are identified in TGF-beta receptor 1 (*TGFBR1*) and *TGFBR2* genes. It has been proposed that patients with the Marfan phenotype and *TGFBR1* or *TGFBR2* mutations be classified as having LDS to properly address the potential for more aggressive vascular disease than seen in MFS (Wright & Connolly, 2021).

The diagnosis of MFS is now established by an *FBNI* pathogenic variant known to be associated with Marfan syndrome AND one of the following: aortic root enlargement (Z-score ≥ 2.0), ectopia lentis, demonstration of aortic root enlargement (Z-score ≥ 2.0) and ectopia lentis OR a defined combination of features throughout the body yielding a systemic score ≥ 7 (Dietz, 2017). These features are summarized in the 2010 Ghent nosology, which is slightly altered for patients under 20 years old (Wright & Connolly, 2021). Due to the identification of *FBNI* as the genetic basis for MFS and its subsequent effects, the understanding of MFS as a structural disorder has become one of a developmental abnormality with broad effects on the morphogenesis and function of multiple organ systems. Importantly, this also introduced new biological targets for treatment strategies in MFS (Dietz et al., 2005; Jensen & Handford, 2016).

Current clinical studies have elucidated a medical regimen for patients with MFS to help control the progression of cardiovascular manifestations and resulting mortality. The standard of care for medical management includes the use of β -blockers with supplementation or replacement by angiotensin receptor blockers (ARBs). However, the best course of treatment is a subject of ongoing research (Bin Mahmood et al., 2017; Hiratzka et al., 2010). However, a Cochrane review concluded, “Based on only one, low-quality RCT comparing long-term propranolol to no treatment in people with Marfan Syndrome, we could draw no definitive conclusions for clinical practice.” The authors

Genetic Testing for Connective Tissue Disorders AHS – M2144

concluded that further, high-quality, randomized trials were needed to evaluate the long-term efficacy of beta-blocker treatment in people with Marfan syndrome (Koo et al., 2017). Sellers et al. (2018) recently reported, “Despite promising preclinical and pilot clinical data, a recent large-scale study using antihypertensive angiotensin II (AngII) receptor type 1 (ATR1) blocker losartan has failed to meet expectations at preventing MFS-associated aortic root dilation, casting doubts about optimal therapy.” Their mouse study suggested that “increased protective endothelial function, rather than ATR1 inhibition or blood pressure lowering, might be of therapeutic significance in preventing aortic root disease in MFS (Sellers et al., 2018).”

Johansen et al. (2020); Ritelli et al. (2020); Shalhub et al. (2020) analyzed vEDS data from 11 institutions between the year 2000 and 2015. Data used for this study included family history, clinical features, diagnostic criteria, demographics, and molecular testing results. A total of 173 individuals were identified for the purposes of this study, with 11 excluded because pathogenic *COL3A1* variants were not identified. Of the remaining individuals, 86 had been diagnosed with a pathogenic *COL3A1* variants, and 76 were diagnosed with only clinical criteria. “Compared with the cohort with pathogenic *COL3A1* variants, the clinical diagnosis only cohort had a higher number of females (80.3% vs 52.3%; $P < .001$), mitral valve prolapse (10.5% vs 1.2%; $P = .009$), and joint hypermobility (68.4% vs 40.7%; $P < .001$). Additionally, they had a lower frequency of easy bruising (23.7% vs 64%; $P < .001$), thin translucent skin (17.1% vs 48.8%; $P < .001$), intestinal perforation (3.9% vs 16.3%; $P = .01$), spontaneous pneumothorax/hemothorax (3.9% vs 14%, $P.03$), and arterial rupture (9.2% vs 17.4%; $P = .13$) (Shalhub et al., 2020).” This study highlights the importance of genetic testing for a vEDS diagnosis as the symptoms of vEDS overlap with many other disorders and a correct diagnosis is necessary for efficient disease treatment. Further, not all *COL3A1* variants are pathogenic, meaning that genetic results must be interpreted by a trained professional.

Using a next-generation sequencing (NGS) multigene panel, Mariath et al. (2019) identified 11 disease-causing variants of EB in a Brazilian population with an efficiency of 94.3%. Other studies that they have included have calculated efficiencies of 83.5% for a panel with 21 genes, 90% with 49 genes, and 97.7% in 21 genes, where all identified mutations were only in five genes. This conveys the clinical utility of gene variants in EB that could be translated to other connective tissue disorder mutations. In a study done with children with inherited EB, the accuracy of several diagnostic techniques, which included electron microscopy (EM), immunofluorescence mapping (IFM), and clinical provisional diagnosis (CPD) was evaluated. It was found that IFM, EM, and CPD yielded an accuracy of 75%, 75%, and 81.5%, respectively (Saunderson et al., 2019). All genetic components, tissue specimen, and clinical history are all necessary for a confirmed EB diagnosis. Li et al. (2021) conducted a study in northwestern China to determine the genotype-phenotype correlation for thoracic aortic aneurysm and dissection via NGS. They screened 15 genes from 212 patients to find that 67 (31.60%) patients in this cohort had a (likely) pathogenic variant, “42 (19.81%) had a variant of uncertain significance (VUS), and 103 (48.58%) had no variant (likely benign/benign/negative),” with 135 reportable variants. With *FBNI*, a gene implicated in MFS, they found that “patients with truncating and splicing mutations are more prone to developing severe aortic dissection than those with missense mutations, especially frameshift mutations (82.76% vs. 42.86%),” and “the positive rate of genetic testing was higher in TAAD patients with family history than in those without (76.74% vs. 18.94%).”

Chen et al. (2021) investigated how genetic testing could aid in avoiding the occurrence of MFS among Chinese families. Using data from 11 families, as well as variant classification and interpretation through pedigree analysis, the researchers were able to support two families who agreed to pre-implantation genetic testing for monogenic diseases (PGT-M) as part of the *in vitro* fertilization process. They were able to identify 11 potential-disease causing *FBNI* variants, and found that “nine variants were classified as likely

Genetic Testing for Connective Tissue Disorders AHS – M2144

pathogenic/pathogenic variants. Among 11 variants, eight variants were missense, and seven of them were located in the Ca-binding EGF-like motifs, moreover, half of them substituted conserved Cysteine residues.” They also found one splice site variant, one frameshift variant, one synonymous variant, and two *de novo* variants. All variants were detected by polymerase chain reaction (PCR). Ultimately, the two MFS families were able to give birth to a baby without the *FBNI* mutation, as the healthy embryo was selected using haplotype analysis “to deduce the embryo’s genotype by using single nucleotide polymorphisms.” This demonstrated the tangible benefits of genetic testing for eliminating MFS and the development of comorbid conditions among future generations.

Guidelines and Recommendations

American College of Cardiology (ACC)

The ACC released guidelines on thoracic aortic disease jointly with the American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. The MFS-specific guidelines are listed below:

- An echocardiogram is recommended at the time of diagnosis of Marfan syndrome to determine the aortic root and ascending aortic diameters and 6 months thereafter to determine the rate of enlargement of the aorta.
- Annual imaging is recommended for patients with Marfan syndrome if stability of the aortic diameter is documented. If the maximal aortic diameter is 4.5 cm or greater, or if the aortic diameter shows significant growth from baseline, more frequent imaging should be considered.
- If a mutant gene (*FBNI*, *TGFBR1*, *TGFBR2*, *COL3A1*, *ACTA2*, *MYH11*) associated with aortic aneurysm and/or dissection is identified in a patient, first-degree relatives should undergo counseling and testing.
- Sequencing of other genes known to cause familial thoracic aortic aneurysms and/or dissection (*TGFBR1*, *TGFBR2*, *MYH11*) may be considered in patients with a family history and clinical features associated with mutations in these genes (Hiratzka et al., 2010).
- Aortic imaging is recommended in patients with LDS or a who have a confirmed genetic mutation known to predispose an individual to aortic aneurysms and aortic dissections (*TGFBR1*, *TGFBR2*, *FBNI*, *ACTA2*, or *MYH11*)

American Heart Association (AHA)

The AHA published a guideline regarding genetic testing for inherited cardiovascular diseases. The AHA notes that genetic testing plays a major role in diagnosing both Loeys-Dietz Syndrome and Marfan Syndrome, as well as confirming diagnoses of familial thoracic aortic aneurysm and dissection. A confirmed diagnosis may then affect timing of treatment or extent of screening for family members of the proband.

The AHA cites an ACMG list of “Genes Associated With Cardiovascular Disorders in Which Secondary/Incidental Findings Are Reportable”. *COL3A1* is listed for Ehlers-Danlos Syndrome and *FBNI*, *TGFBR1*, *TGFBR2*, *SMAD3*, *ACTA2*, *MYH11* are listed for Marfan syndrome, Loeys-Dietz syndromes, and familial thoracic aortic aneurysms and dissections.

The AHA then lists another ACMG list of “Lists of Genes to Be Considered for Testing From Guidelines and Statements”. Regarding heritable thoracic aortic aneurysm(s) or

Genetic Testing for Connective Tissue Disorders AHS – M2144

dissection(s), the genes *ACTA2*, *COL3A1*, *FBNI*, *MYH11*, *SMAD3*, *TGFB2*, *TGFBRI*, *TGFB2*, *MYLK*, *LOX*, *PRKG1* are listed as having “definitive or strong evidence”, and the genes *EFEMP2*, *ELN*, *FBN2*, *FLNA*, *NOTCH1*, *SLC2A10*, *SMAD4*, *SKI*, are considered as “potentially diagnostic” (Musunuru et al., 2020).

American College of Medical Genetics (ACMG)

The ACMG recommends the following diagnostic evaluations for a MFS diagnosis: a physical exam, family history, echocardiogram, dilated eye exam, CT or MRI, and the consideration of *FBNI* gene sequencing (Pyeritz, 2012). The ACMG notes that, since *FBNI* mutations may cause conditions other than MFS (such as EDS and LDS), clinical features must be used to diagnose MFS properly. The ACMG further notes *SMAD3*, *ACTA2*, and *MYH11* as potential genes of interest in identifying MFS, in addition to *FBNI*, *TGFBRI*, and *TGFB2* (Pyeritz, 2012).

Regarding LDS, the ACMG notes that “LDS strongly resembles the vascular form of Ehlers–Danlos syndrome, especially in terms of thin skin” (Pyeritz, 2012). Further, a diagnostic evaluation of LDS includes the following: a “physical exam, family history, echocardiogram, dilated eye exam (to exclude MFS), magnetic resonance angiography of the head, neck thorax, abdomen and pelvis, and *TGFBRI* and *TGFB2* gene sequencing (Pyeritz, 2012).” Specifically, the ACMG states that “In a patient found to have consistent facial features, bifid uvula, and arterial tortuosity, the diagnosis [of LDS] can be confirmed with *TGFB2* testing (Pyeritz, 2012).”

Regarding EDS hypermobile type, the ACMG recommends the following diagnostic evaluation: a physical exam, family history, echocardiogram and dilated eye exam (to exclude MFS). The guidelines also specifically state that “Diagnosis is based on clinical evaluation and family history. A small subset of individuals with the hypermobile form of EDS have an insertion or deletion in the *TNXB* gene” (Pyeritz, 2012).

ACMG also published a statement titled “Recommendations for reporting of secondary findings in clinical exome and genome sequencing”. In it, *COL3A1* is listed for Ehlers–Danlos Syndrome, vascular type, and *FBNI*, *TGFBRI*, *TGFB2*, *SMAD3*, *ACTA2*, and *MYH11* were listed as relevant genes for autosomal dominant aortopathies (Miller, Lee, Chung, et al., 2021; Miller, Lee, Gordon, et al., 2021).

American Academy of Pediatrics (AAP)

The AAP has released guidelines on the management of supervision of children with MFS. However, they allude to genetic testing of *FBNI*, stating it is “best reserved” for patients with “strong clinical suspicion” of MFS. The AAP states that younger patients (18 and under) should be evaluated periodically instead of undergoing genetic testing (Tinkle & Saal, 2013).

The Marfan Foundation

The Marfan Foundation has released recommendations on certain aspects of testing for MFS. The Foundation mentions several situations in which genetic testing may be useful, such as patients with features of multiple disorders, patients with a clinical symptom characteristic of MFS (such as ectopia lentis), children of parents affected by MFS, or adults with MFS that are considering having children. Prenatal testing may be performed, either a chorionic villus sampling (CVS) at 10-11 weeks or amniocentesis at 16-18 weeks. However, the parent’s mutation must be confirmed before proceeding with either prenatal test (“Genetic Testing and Marfan Syndrome,” 2013).

Genetic Testing for Connective Tissue Disorders AHS – M2144

Screening of first-degree relatives of patients with MFS is also warranted. Aortic imaging may be performed if the mutation has not been identified (*Overview of Cardiac Management in Marfan Syndrome*, 2015).

International Consortium on the Ehlers-Danlos Syndromes

These guidelines state that Ehlers-Danlos syndrome “Molecular diagnostic strategies should rely on NGS technologies, which offer the potential for parallel sequencing of multiple genes. Targeted resequencing of a panel of genes, for example, *COL5A1*, *COL5A2*, *COL1A1* and *COL1A2*, is a time- and cost-effective approach for the molecular diagnosis of the genetically heterogeneous EDS. When no mutation (or in case of an autosomal recessive condition only one mutation) is identified, this approach should be complemented with a copy number variant (CNV) detection strategy to identify large deletions or duplications, for example Multiplex Ligation-dependent Probe Amplification (MLPA), qPCR, or targeted array analysis. Alternatively, or in a second phase, whole exome sequencing (WES) or whole genome sequencing (WGS) and RNA sequencing techniques can be used, with data-analysis initially focusing on the genes of interest for a given EDS subtype. In absence of the identification of a causal mutation, this approach allows to expand the analysis to other genes within the genome. This is particularly interesting in view of the clinical overlap between EDS subtypes and with other HCTDs, and the observation that in an important proportion of EDS-patients, no pathogenic variants are identified in any of the known EDS-associated genes (Malfait et al., 2017).”

For cEDS, the following guidelines were given:

- “Molecular screening by means of targeted resequencing of a gene panel that includes at least the *COL5A1*, *COL5A2*, *COL1A1*, and *COL1A2* genes, or by WES or WGS, is indicated. When no mutation is identified, this approach should be complemented with a CNV detection strategy to identify large deletions or duplications.
- Absence of these confirmatory findings does not exclude the diagnosis, as specific types of mutations (e.g., deep intronic mutations) may go undetected by standard diagnostic molecular techniques; however, alternative diagnoses should be considered in the absence of (a) *COL5A1*, *COL5A2*, *COL1A1*, or *COL1A2* mutation(s) (Malfait et al., 2017).”

For classical-like EDS (cIEDS), the following guidelines were given:

- “Molecular analysis of the *TNXB* gene should be used as the standard confirmatory test. Difficulties in DNA testing are related to the presence of a pseudogene (*TNXA*), which is more than 97% identical to the 3' end of *TNXB* (exons 32–44). With the only exception of exon 35, which partially shows a *TNXB*-specific sequence, exon and intron sequences in this region are identical or almost identical in both the gene and the pseudogene. This has implications both for sequencing and deletion/duplication analysis.
- For sequence analysis of *TNXB*, two approaches are recommended.
 - Sanger sequencing of the entire *TNXB* gene.
 - Next-generation sequencing of *TNXB* + Sanger sequencing of the pseudogene region.”
- If no or only one causative mutation is identified by classic sequencing, additional methods that allow detection of large deletions/duplications should be added. So far no method is able to specifically detect *TNXB* CNVs in the highly homologous exons 32–34 and 36–44. CNV analysis of exon 35 is currently used to detect deletions in this region, including the 30 kb deletion
- Absence of these confirmatory findings does not exclude the diagnosis, as specific types of mutations (e.g., deep intronic mutations) may go undetected by standard

Genetic Testing for Connective Tissue Disorders AHS – M2144

diagnostic molecular techniques; however, alternative diagnoses should be considered in the absence of a TNXB mutation (Malfait et al., 2017).”

For cardiac-valvular EDS (cvEDS), the following recommendations were given:

- “Molecular screening by Sanger sequencing of *COL1A2*, or targeted resequencing of a gene panel that includes *COL1A2* is indicated. When no mutation is identified, this approach should be complemented with a CNV detection strategy to identify large deletions or duplications.
- In case of unavailability of genetic testing, SDS PAGE demonstrates total absence of (pro-) $\alpha 2(I)$ collagen chains.
- Whereas absence of these confirmatory biochemical findings allows to exclude the diagnosis of cvEDS, absence of these confirmatory genetic findings does not exclude the diagnosis, as specific types of mutations (e.g., deep intronic mutations) may go undetected by standard diagnostic molecular techniques (Malfait et al., 2017).”

For vEDS, the following guidelines were given:

- “Molecular screening by Sanger sequencing of *COL3A1*, or targeted resequencing of a gene panel that includes *COL3A1* and *COL1A1* (the latter to identify the above-listed arginine-to-cysteine substitution mutations) is indicated. When no mutation is identified, this approach should be complemented with a CNV detection strategy to identify large deletions or duplications.
- Absence of these confirmatory findings does not exclude the diagnosis, as specific types of mutations (e.g., deep intronic mutations) may go undetected by standard diagnostic molecular techniques; however, alternative diagnoses should be considered in the absence of a *COL3A1* or *COL1A1* mutation (Malfait et al., 2017).”

For hypermobile EDS (hEDS), the following guidelines were given:

- “The diagnosis of hEDS remains clinical as there is yet no reliable or appreciable genetic etiology to test for in the vast majority of patients (Malfait et al., 2017).”

For arthrochalasia EDS (aEDS), the following guideline were given:

- “Molecular screening by Sanger sequencing of *COL1A1* and *COL1A2*, or targeted resequencing of a gene panel that includes these genes, is indicated. When no mutation is identified, this approach should be complemented with a CNV detection strategy to identify large deletions or duplications.
- In case of unavailability of genetic testing, SDS PAGE of the pepsin-digested collagen in the medium or cell layer of cultured dermal fibroblasts demonstrates the presence of a mutant pN α 1(I) or pN α 2(I) chain (precursor procollagen chains in which the carboxy (C)-but not the amino (N)-propeptide is cleaved off).
- TEM of skin specimens shows loosely and randomly organized collagen fibrils with a smaller and more variable diameter, and an irregular outline. These findings may support the diagnosis, but cannot confirm it.
- Absence of a causative mutation in *COL1A1* or *COL1A2* that leads to complete or partial deletion of the exon 6 of either gene excludes the diagnosis of aEDS (Malfait et al., 2017).”

For dermatosparaxis EDS (dEDS), the following guidelines were given:

- “Molecular screening by Sanger sequencing of targeted resequencing of a gene panel that includes *ADAMTS2* is indicated. When no, or only one, causative mutation is identified, this approach should be complemented with a CNV detection strategy to identify large deletions or duplications.

Genetic Testing for Connective Tissue Disorders AHS – M2144

- In case of unavailability of genetic testing, SDS, PAGE demonstrates presence of pN α 1(I) and pN α 2(I) chains of type I procollagen extracted from dermis in the presence of protease inhibitors or detected in fibroblast cultures.
- TEM shows collagen fibrils in affected skin specimens with a hieroglyphic pattern. These ultrastructural findings are usually typical but may be almost indistinguishable from those observed in aEDS. As such, they are not sufficient to confirm the diagnosis.
- Absence of these confirmatory findings does not exclude the diagnosis of dEDS, as specific types of mutations (e.g., deep intronic mutations) may go undetected by standard diagnostic molecular techniques; however, alternative diagnoses should be considered in the absence of ADAMTS2 mutations (Malfait et al., 2017).”

For kyphoscoliotic (kEDS), the following recommendations were given:

- Laboratory confirmation of kEDS should start with the quantification of deoxyypyridinoline (Dpyr or LP for lysyl-pyridinoline) and pyridinoline (Pyr or HP for hydroxylysyl-pyridinoline) cross-links in urine quantitated by means of high-performance liquid chromatography (HPLC). An increased Dpyr/Pyr ratio is a highly sensitive and specific test for kEDS caused by biallelic *PLOD1* mutations (kEDS-*PLOD1*), but is normal for biallelic *FKBP14* mutations (kEDS-*FKBP14*).
- The normal ratio of Dpyr/Pyr cross-links is approximately 0.2, whereas in kEDS-*PLOD1* the ratio is significantly increased (approximately 10–40 times increase, range 2–9). This method is fast and cost-effective and it can also be used to determine the pathogenic status of a VUS in *PLOD1*.
- SDS–PAGE may detect faster migration of underhydroxylated collagen chains and their derivatives in kEDS-*PLOD1* but not in kEDS-*FKBP14*. However, abnormalities in migration can be subtle.
- Molecular analysis for kEDS-*PLOD1* may start with MLPA analysis of *PLOD1*, for the evaluation of the common intragenic duplication in *PLOD1* caused by an Alu-Alu recombination between introns 9 and 16 (the most common mutant allele) [Hautala et al., 1993].
- Molecular screening by means of targeted resequencing of a gene panel that includes *PLOD1* and *FKBP14*, is indicated when MLPA of *PLOD1* fails to identify the common duplication. Such a gene panel may also include other genes associated with phenotypes that clinically overlap with kEDS, such as *ZNF469*, *PRDM5*, *B4GALT7*, *B3GALT6*, *SLC39A13*, *CHST14* and *DSE*. Alternatively, WES may be performed. When no, or only one, causative mutation is identified, this approach should be complemented with a CNV detection strategy to identify large deletions or duplications in these genes.
- TEM on skin specimens has shown variable diameters and abnormal contours of the collagen fibrils and irregular interfibrillar space, but these abnormalities are not unique to this condition. As such, whereas TEM on a skin biopsy can support diagnosis, it cannot confirm it.
- Whereas absence of an abnormal urinary LP/HP ratio excludes the diagnosis of kEDS-*PLOD1*, absence of the confirmatory genetic findings does not exclude the diagnosis of kEDS, as specific types of mutations (e.g., deep intronic mutations) may go undetected by standard diagnostic molecular techniques and/or other, yet to be discovered, genes, may be associated with this phenotype; however, alternative diagnoses should be considered in the absence of *PLOD1* or *FKBP14* mutations (Malfait et al., 2017).”

For brittle cornea syndrome (BCS), the following guidelines were given:

- “Molecular screening by means of targeted resequencing of a gene panel that includes *ZNF469* and *PRDM5* is indicated. Such a gene panel may also include other genes associated with phenotypes that clinically overlap with BCS, such as *PLOD1*, *FKBP14*, *B4GALT7*, *B3GALT6*, *SLC39A13*, *CHST14*, and *DSE*.

Genetic Testing for Connective Tissue Disorders AHS – M2144

Alternatively, WES may be performed. When no, or only one, causative mutation is identified, this approach should be complemented with a CNV detection strategy to identify large deletions or duplications in these genes.

- Absence of these confirmatory findings does not exclude the diagnosis, as specific types of mutations (e.g., deep intronic mutations) may go undetected by standard diagnostic molecular techniques, and other, yet unknown genes, might be associated with BCS (Malfait et al., 2017).”

For spondylodysplastic EDS (spEDS), the following guidelines were given:

- Molecular screening by means of targeted resequencing of a gene panel that includes *B4GALT7*, *B3GALT6*, and *SLC39A13* is indicated. Such a gene panel may also include other genes associated with phenotypes that clinically overlap with spEDS, such as *PLOD1*, *FKBP14*, *ZNF469*, *PRDM5*, *CHST14*, and *DSE*. Alternatively, WES may be performed. When no, or only one, causative mutation is identified, this approach should be complemented with a CNV detection strategy to identify large deletions or duplications in these genes.
- For definite proof of GAG deficiency (*B4GALT7* and *B3GALT6* mutations), biochemical methods to assess GAG synthesis in patients’ cultured fibroblasts are currently available in many specialized laboratories.
- The laboratory measurement of urinary pyridinolines, lysyl-pyridinoline (LP) and hydroxyllysyl-pyridinoline (HP) quantitated by HPLC allows the detection of an increased ratio LP/HP to approximately 1, (compared to a normal values of approximately 0.2) in patients with mutations in *SLC39A13*. This fast and cost-effective method can also be used to determine the pathogenic status of a VUS (see also “verification of diagnosis” in kEDS-PLOD1).
- Absence of confirmatory genetic findings does not exclude the diagnosis of spEDS, as specific types of mutations (eg deep intronic mutations) may go undetected by standard diagnostic molecular techniques, and still other, yet to be discovered, genes may be associated with these phenotypes. In case no *B4GALT7*, *B3GALT6*, or *SCL39A13* mutations are identified, alternative diagnoses should however be considered (Malfait et al., 2017).”

For musculocontractural EDS (mcEDS), the following guidelines were given:

- “Molecular screening by means of targeted resequencing of a gene panel that includes *CHST14* and *DSE* is indicated. Such a gene panel may also include other genes associated with phenotypes that clinically overlap with mcEDS, such as *PLOD1*, *FKBP14*, *ZNF469*, *PRDM5*, *B4GALT7*, *B3GALT6* and *SLC39A13*. Alternatively, WES may be performed. When no, or only one, causative mutation is identified, this approach should be complemented with a CNV detection strategy to identify large deletions or duplications in these genes.
- Absence of these confirmatory genetic findings does not exclude the diagnosis of mcEDS, as specific types of mutations (e.g., deep intronic mutations) may go undetected by standard diagnostic molecular techniques. In case no *CHST14* or *DSE* mutations are identified, alternative diagnoses should be considered (Malfait et al., 2017).”

For myopathic EDS (mEDS), the following guidelines were given:

- “Molecular screening by means of targeted resequencing of a gene panel that includes *COL12A1* is indicated. Such a gene panel may also include other genes associated with phenotypes that clinically overlap with mEDS, such as *COL6A1*, *COL6A2*, *COL6A3*. Alternatively, WES may be performed. When no, or only one, causative mutation is identified, this approach should be complemented with a CNV detection strategy to identify large deletions or duplications in these genes.
- Absence of these confirmatory findings does not exclude the diagnosis, as specific types of mutations (eg deep intronic mutations) may go undetected by standard

Genetic Testing for Connective Tissue Disorders AHS – M2144

diagnostic molecular techniques, and other, yet to be discovered, genes may be associated with this phenotype (Malfait et al., 2017).”

For periodontal EDS (pEDS), the following guidelines were given:

- “Identification of known or compatible mutations by sequence analysis of C1R and C1S. Large deletions or null mutations that completely remove C1r or C1s protein function do not cause pEDS.
- At present it cannot be stated whether absence of a C1R or C1S mutations excludes the diagnosis because the experience with the molecular diagnosis is limited (Malfait et al., 2017).”

Canadian Cardiovascular Society (CCS)

The CCS has published recommendations for MFS stating a strong recommendation for clinical and genetic screening for anyone with suspected MFS “to clarify the nature of the disease and provide a basis for individual genetic counseling” (Boodhwani et al., 2014).

The CCS also published recommendations for non-Marfan genetic forms of aortic disease such as thoracic aortic disease (TAD). These guidelines state that “We recommend screening for TAD-associated genes in non-BAV aortopathy index cases to clarify the origin of disease and improve clinical and genetic counselling (Boodhwani et al., 2014).” These guidelines also state that individuals with a known LDS mutation (such as *TGFBR1/2*, *TGFB*, *SMAD3*, *ACTA2*, or *MYH11*) should receive complete aortic imaging when diagnosed and 6 months after diagnosis.

The Ehlers Danlos Society

The Ehlers Danlos Society published the 2017 International EDS Classification document which includes required clinical criteria for an EDS diagnosis.

For cEDS, the Ehlers Danlos Society has stated that “Molecular analysis of *COL5A1* and *COL5A2* genes identifies a causal mutation in more than 90% of the patients and should be used as the standard confirmatory test. In case of unavailability of genetic testing, electron microscopy findings of collagen flowers on skin biopsy can support the clinical diagnosis (EDS, 2017).”

For vEDS, the Ehlers Danlos Society has stated that “The diagnosis of vEDS rests on the identification of a causative variant in one allele of *COL3A1* (EDS, 2017).”

International Group of Specialists with a Broad Aggregate Experience in the Care of Individuals with Vascular EDS

Recommendations made by this group of vEDS specialists recommend to “identify causative variants in *COL3A1* prior to [the] application of diagnosis” of vEDS (Byers et al., 2017).

National Organization for Rare Disorders (NORD)

NORD has posted recommendations on EB stating that “When EB is suspected, a skin biopsy should be obtained and sent to an appropriate laboratory to confirm the diagnosis with transmission electron microscopy (TEM) and/or immunofluorescent antibody/antigen mapping. Molecular genetic testing for mutations in most of the genes known to be associated with the various types of EB is clinically available (NORD, 2013).”

On the diagnosis of EDS, the NORD has stated that diagnosis is generally made using patient histories and clinical findings, and that genetic testing can help in the diagnosis of

Genetic Testing for Connective Tissue Disorders AHS – M2144

some subtypes. Electron microscopic analysis could also aid in revealing the collagen abnormalities seen in EDS. “The clinical evaluation of individuals with suspected or diagnosed EDS typically includes assessments to detect and determine the extent of skin and joint hyperextensibility.” The NORD also posted recommendations of utilizing computerized tomography (CT) scanning, magnetic resonance imaging (MRI), and echocardiography to observe any mitral valve prolapse and aortic dilatation. On kEDS, NORD has written of confirmatory tests using “either a urine sample and extrapolated ratio of deoxypyridinoline to pyridinoline cross-links, or on a skin biopsy sample and measurement of lysyl hydroxylase enzyme activity from skin fibroblast cells” (NORD, 2017)

Applicable Federal Regulations

Many labs have developed specific tests that they must validate and perform in house. These laboratory-developed tests (LDTs) are regulated by the Centers for Medicare and Medicaid (CMS) as high-complexity tests under the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88). As an LDT, the U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use.

Billing/Coding/Physician Documentation Information

This policy may apply to the following codes. Inclusion of a code in this section does not guarantee that it will be reimbursed. For further information on reimbursement guidelines, please see Administrative Policies on the Blue Cross Blue Shield of North Carolina web site at www.bcbsnc.com. They are listed in the Category Search on the Medical Policy search page.

Applicable service codes: 81405, 81408, 81410, 81411

BCBSNC may request medical records for determination of medical necessity. When medical records are requested, letters of support and/or explanation are often useful, but are not sufficient documentation unless all specific information needed to make a medical necessity determination is included.

Scientific Background and Reference Sources

For policy titled: Marfan Syndrome AHS – M2144

Becerra-Munoz, V. M., Gomez-Doblas, J. J., Porrás-Martin, C., Such-Martinez, M., Crespo-Leiro, M. G., Barriales-Villa, R., . . . Cabrera-Bueno, F. (2018). The importance of genotype-phenotype correlation in the clinical management of Marfan syndrome. *Orphanet J Rare Dis*, 13(1), 16. doi:10.1186/s13023-017-0754-6

Bin Mahmood, S. U., Velasquez, C. A., Zafar, M. A., Saeyeldin, A. A., Brownstein, A. J., Ziganshin, B. A., . . . Mukherjee, S. K. (2017). Medical management of aortic disease in Marfan syndrome. *Ann Cardiothorac Surg*, 6(6), 654-661. doi:10.21037/acs.2017.11.09

Dale, M., Fitzgerald, M. P., Liu, Z., Meisinger, T., Karpisek, A., Purcell, L. N., . . . Xiong, W. (2017). Premature aortic smooth muscle cell differentiation contributes to matrix dysregulation in Marfan Syndrome. *PLoS One*, 12(10), e0186603. doi:10.1371/journal.pone.0186603

Davis, M. R., & Summers, K. M. (2012). Structure and function of the mammalian fibrillin gene family: implications for human connective tissue diseases. *Mol Genet Metab*, 107(4), 635-647. doi:10.1016/j.ymgme.2012.07.023

Dietz, H. (2017). Marfan Syndrome. In M. P. Adam, H. H. Ardinger, R. A. Pagon, S. E. Wallace, L. J. H. Bean, K. Stephens, & A. Amemiya (Eds.), *GeneReviews*(R). Seattle (WA): University of

Genetic Testing for Connective Tissue Disorders AHS – M2144

Washington, Seattle University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/20301510>.

Dietz, H. C., Loeys, B., Carta, L., & Ramirez, F. (2005). Recent progress towards a molecular understanding of Marfan syndrome. *Am J Med Genet C Semin Med Genet*, 139c(1), 4-9. doi:10.1002/ajmg.c.30068

Faivre, L., Collod-Beroud, G., Loeys, B., Child, A., Binquet, C., Gautier, E., . . . Boileau, C. (2007). Effect of Mutation Type and Location on Clinical Outcome in 1,013 Proband with Marfan Syndrome or Related Phenotypes and FBN1 Mutations: An International Study. *Am J Hum Genet*, 81(3), 454-466.

FDA. (2018).

Foundation, M. (2013a). GENETIC TESTING AND MARFAN SYNDROME.

Foundation, M. (2013b). OVERVIEW OF CARDIAC MANAGEMENT IN MARFAN SYNDROME.

Grewal, N., & Gittenberger-de Groot, A. C. (2018). Pathogenesis of aortic wall complications in Marfan syndrome. *Cardiovasc Pathol*, 33, 62-69. doi:10.1016/j.carpath.2018.01.005

Hilhorst-Hofstee, Y., Rijlaarsdam, M. E., Scholte, A. J., Swart-van den Berg, M., Versteegh, M. I., van der Schoot-van Velzen, I., . . . Pals, G. (2010). The clinical spectrum of missense mutations of the first aspartic acid of cbEGF-like domains in fibrillin-1 including a recessive family. *Hum Mutat*, 31(12), E1915-1927. doi:10.1002/humu.21372

Hiratzka, L. F., Bakris, G. L., Beckman, J. A., Bersin, R. M., Carr, V. F., Casey, D. E., Jr., . . . Williams, D. M. (2010). 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. *Circulation*, 121(13), e266-369. doi:10.1161/CIR.0b013e3181d4739e

Jensen, S. A., & Handford, P. A. (2016). New insights into the structure, assembly and biological roles of 10-12 nm connective tissue microfibrils from fibrillin-1 studies. *Biochem J*, 473(7), 827-838. doi:10.1042/bj20151108

Judge, D. P., & Dietz, H. C. (2005). Marfan's syndrome. *Lancet*, 366(9501), 1965-1976. doi:10.1016/s0140-6736(05)67789-6

Kalia, S. S., Adelman, K., Bale, S. J., Chung, W. K., Eng, C., Evans, J. P., . . . Miller, D. T. (2017). Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. *Genet Med*, 19(2), 249-255. doi:10.1038/gim.2016.190

Koo, H. K., Lawrence, K. A., & Musini, V. M. (2017). Beta-blockers for preventing aortic dissection in Marfan syndrome. *Cochrane Database Syst Rev*, 11, Cd011103. doi:10.1002/14651858.CD011103.pub2

Loeys, B., De Backer, J., Van Acker, P., Wettinck, K., Pals, G., Nuytinck, L., . . . De Paepe, A. (2004). Comprehensive molecular screening of the FBN1 gene favors locus homogeneity of classical Marfan syndrome. *Hum Mutat*, 24(2), 140-146. doi:10.1002/humu.20070

Genetic Testing for Connective Tissue Disorders AHS – M2144

Loeys, B., & Dietz, H. (2018, 03/01/2018). Loeys-Dietz Syndrome. GGeneReviews (R). Retrieved from <https://www.ncbi.nlm.nih.gov/books/NBK1133/>

Loeys, B. L., Dietz, H. C., Braverman, A. C., Callewaert, B. L., De Backer, J., Devereux, R. B., . . . De Paepe, A. M. (2010). The revised Ghent nosology for the Marfan syndrome. *Journal of Medical Genetics*, 47(7), 476. doi:10.1136/jmg.2009.072785

Nataatmadja, M., West, M., West, J., Summers, K., Walker, P., Nagata, M., & Watanabe, T. (2003). Abnormal extracellular matrix protein transport associated with increased apoptosis of vascular smooth muscle cells in marfan syndrome and bicuspid aortic valve thoracic aortic aneurysm. *Circulation*, 108 Suppl 1, Ii329-334. doi:10.1161/01.cir.0000087660.82721.15

Neptune, E. R., Frischmeyer, P. A., Arking, D. E., Myers, L., Bunton, T. E., Gayraud, B., . . . Dietz, H. C. (2003). Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. *Nat Genet*, 33(3), 407-411. doi:10.1038/ng1116

Pyeritz, R. E. (2012). Evaluation of the adolescent or adult with some features of Marfan syndrome. *Genet Med*, 14(1), 171-177. doi:10.1038/gim.2011.48

Pyeritz, R. E. (2017). Etiology and pathogenesis of the Marfan syndrome: current understanding. *Ann Cardiothorac Surg*, 6(6), 595-598. doi:10.21037/acs.2017.10.04

Radke, R. M., & Baumgartner, H. (2014). Diagnosis and treatment of Marfan syndrome: an update. *Heart*, 100(17), 1382-1391. doi:10.1136/heartjnl-2013-304709

Sellers, S. L., Milad, N., Chan, R., Mielnik, M., Jermilova, U., Huang, P. L., . . . Bernatchez, P. (2018). Inhibition of Marfan Syndrome Aortic Root Dilation by Losartan: Role of Angiotensin II Receptor Type 1-Independent Activation of Endothelial Function. *Am J Pathol*, 188(3), 574-585. doi:10.1016/j.ajpath.2017.11.006

Tinkle, B. T., & Saal, H. M. (2013). Health Supervision for Children With Marfan Syndrome. *Pediatrics*, 132(4), e1059. doi:10.1542/peds.2013-2063

Wright, M., & Connolly, H. (2018). Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders - UpToDate. In H. Dietz (Ed.), *UpToDate*. Retrieved from https://www.uptodate.com/contents/genetics-clinical-features-and-diagnosis-of-marfan-syndrome-and-related-disorders?search=marfan&source=search_result&selectedTitle=1~125&usage_type=default&display_rank=1#H559172.

For policy titled: Genetic Testing for Connective Tissue Disorder

Becerra-Munoz, V. M., Gomez-Doblas, J. J., Porras-Martin, C., Such-Martinez, M., Crespo-Leiro, M. G., Barriales-Villa, R., de Teresa-Galvan, E., Jimenez-Navarro, M., & Cabrera-Bueno, F. (2018). The importance of genotype-phenotype correlation in the clinical management of Marfan syndrome. *Orphanet J Rare Dis*, 13(1), 16. <https://doi.org/10.1186/s13023-017-0754-6>

Bin Mahmood, S. U., Velasquez, C. A., Zafar, M. A., Saeyeldin, A. A., Brownstein, A. J., Ziganshin, B. A., Elefteriades, J. A., & Mukherjee, S. K. (2017). Medical management of aortic disease in Marfan syndrome. *Ann Cardiothorac Surg*, 6(6), 654-661. <https://doi.org/10.21037/acs.2017.11.09>

Boodhwani, M., Andelfinger, G., Leipsic, J., Lindsay, T., McMurtry, M. S., Therrien, J., & Siu, S. C. (2014). Canadian Cardiovascular Society position statement on the management of thoracic aortic disease. *Can J Cardiol*, 30(6), 577-589. <https://doi.org/10.1016/j.cjca.2014.02.018>

Byers, P. H., Belmont, J., Black, J., De Backer, J., Frank, M., Jeunemaitre, X., Johnson, D., Pepin, M., Robert, L., Sanders, L., & Wheeldon, N. (2017). Diagnosis, natural history, and management

Genetic Testing for Connective Tissue Disorders AHS – M2144

- in vascular Ehlers-Danlos syndrome. *Am J Med Genet C Semin Med Genet*, 175(1), 40-47. <https://doi.org/10.1002/ajmg.c.31553>
- Chen, S., Fei, H., Zhang, J., Chen, Y., Huang, H., Lu, D., & Xu, C. (2021). Classification and Interpretation for 11 FBN1 Variants Responsible for Marfan Syndrome and Pre-implantation Genetic Testing (PGT) for Two Families Successfully Blocked Transmission of the Pathogenic Mutations. *Front Mol Biosci*, 8, 749842. <https://doi.org/10.3389/fmolb.2021.749842>
- Coulombe, P. A., Hutton, M. E., Letai, A., Hebert, A., Paller, A. S., & Fuchs, E. (1991). Point mutations in human keratin 14 genes of epidermolysis bullosa simplex patients: genetic and functional analyses. *Cell*, 66(6), 1301-1311. [https://doi.org/10.1016/0092-8674\(91\)90051-y](https://doi.org/10.1016/0092-8674(91)90051-y)
- Dale, M., Fitzgerald, M. P., Liu, Z., Meisinger, T., Karpisek, A., Purcell, L. N., Carson, J. S., Harding, P., Lang, H., Koutakis, P., Batra, R., Mietus, C. J., Casale, G., Pipinos, I., Baxter, B. T., & Xiong, W. (2017). Premature aortic smooth muscle cell differentiation contributes to matrix dysregulation in Marfan Syndrome. *PLoS One*, 12(10), e0186603. <https://doi.org/10.1371/journal.pone.0186603>
- Davis, M. R., & Summers, K. M. (2012). Structure and function of the mammalian fibrillin gene family: implications for human connective tissue diseases. *Mol Genet Metab*, 107(4), 635-647. <https://doi.org/10.1016/j.ymgme.2012.07.023>
- Dietz, H. (2017). Marfan Syndrome. In M. P. Adam, H. H. Ardinger, R. A. Pagon, S. E. Wallace, L. J. H. Bean, K. Stephens, & A. Amemiya (Eds.), *GeneReviews(R)*. University of Washington, Seattle University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved. <https://www.ncbi.nlm.nih.gov/pubmed/20301510>
- Dietz, H. C., Loeys, B., Carta, L., & Ramirez, F. (2005). Recent progress towards a molecular understanding of Marfan syndrome. *Am J Med Genet C Semin Med Genet*, 139c(1), 4-9. <https://doi.org/10.1002/ajmg.c.30068>
- EDS. (2017). *2017 International EDS Classification*. https://ehlers-danlos.com/wp-content/uploads/2017-EDS-Classification_March_2017.pdf
- Faivre, L., Collod-Beroud, G., Loeys, B., Child, A., Binquet, C., Gautier, E., Callewaert, B., Arbustini, E., Mayer, K., Arslan-Kirchner, M., Kiotsekoglou, A., Comeglio, P., Marziliano, N., Dietz, H., Halliday, D., Beroud, C., Bonithon-Kopp, C., Claustres, M., Muti, C., . . . Boileau, C. (2007). Effect of Mutation Type and Location on Clinical Outcome in 1,013 Proband with Marfan Syndrome or Related Phenotypes and FBN1 Mutations: An International Study. *Am J Hum Genet*, 81(3), 454-466. <https://www.ncbi.nlm.nih.gov/pubmed/17701892>
- Genetic Testing and Marfan Syndrome*. (2013). The Marfan Foundation. <http://info.marfan.org/genetic-testing-and-marfan-syndrome>
- Grewal, N., & Gittenberger-de Groot, A. C. (2018). Pathogenesis of aortic wall complications in Marfan syndrome. *Cardiovasc Pathol*, 33, 62-69. <https://doi.org/10.1016/j.carpath.2018.01.005>
- Hiratzka, L. F., Bakris, G. L., Beckman, J. A., Bersin, R. M., Carr, V. F., Casey, D. E., Jr., Eagle, K. A., Hermann, L. K., Isselbacher, E. M., Kazerooni, E. A., Kouchoukos, N. T., Lytle, B. W., Milewicz, D. M., Reich, D. L., Sen, S., Shinn, J. A., Svensson, L. G., & Williams, D. M. (2010). 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. *Circulation*, 121(13), e266-369. <https://doi.org/10.1161/CIR.0b013e318d4739e>
- Jensen, S. A., & Handford, P. A. (2016). New insights into the structure, assembly and biological roles of 10-12 nm connective tissue microfibrils from fibrillin-1 studies. *Biochem J*, 473(7), 827-838. <https://doi.org/10.1042/bj20151108>
- Johansen, H., Velvin, G., & Lidal, I. (2020). Adults with Loeys-Dietz syndrome and vascular Ehlers-Danlos syndrome: A cross-sectional study of health burden perspectives. *Am J Med Genet A*, 182(1), 137-145. <https://doi.org/10.1002/ajmg.a.61396>
- Jud, P., & Hafner, F. (2019). Vascular Involvement in Loeys-Dietz Syndrome. *Mayo Clin Proc*, 94(6), 1117-1119. <https://doi.org/10.1016/j.mayocp.2018.12.030>

Genetic Testing for Connective Tissue Disorders AHS – M2144

- Koo, H. K., Lawrence, K. A., & Musini, V. M. (2017). Beta-blockers for preventing aortic dissection in Marfan syndrome. *Cochrane Database Syst Rev*, 11, Cd011103. <https://doi.org/10.1002/14651858.CD011103.pub2>
- Li, J., Yang, L., Diao, Y., Zhou, L., Xin, Y., Jiang, L., Li, R., Wang, J., Duan, W., & Liu, J. (2021). Genetic testing and clinical relevance of patients with thoracic aortic aneurysm and dissection in northwestern China. *Mol Genet Genomic Med*, 9(10), e1800. <https://doi.org/10.1002/mgg3.1800>
- Loeys, B., De Backer, J., Van Acker, P., Wettinck, K., Pals, G., Nuytinck, L., Coucke, P., & De Paepe, A. (2004). Comprehensive molecular screening of the FBN1 gene favors locus homogeneity of classical Marfan syndrome. *Hum Mutat*, 24(2), 140-146. <https://doi.org/10.1002/humu.20070>
- Loeys, B., & Dietz, H. (2018, 03/01/2018). *Loeys-Dietz Syndrome*. University of Washington, Seattle. Retrieved 01/08/2019 from <https://www.ncbi.nlm.nih.gov/books/NBK1133/>
- Loeys, B. L., Dietz, H. C., Braverman, A. C., Callewaert, B. L., De Backer, J., Devereux, R. B., Hilhorst-Hofstee, Y., Jondeau, G., Faivre, L., Milewicz, D. M., Pyeritz, R. E., Sponseller, P. D., Wordworth, P., & De Paepe, A. M. (2010). The revised Ghent nosology for the Marfan syndrome. *Journal of Medical Genetics*, 47(7), 476. <https://doi.org/10.1136/jmg.2009.072785>
- MacCarrick, G., Black, J. H., 3rd, Bowdin, S., El-Hamamsy, I., Frischmeyer-Guerrero, P. A., Guerrero, A. L., Sponseller, P. D., Loeys, B., & Dietz, H. C., 3rd. (2014). Loeys-Dietz syndrome: a primer for diagnosis and management. *Genet Med*, 16(8), 576-587. <https://doi.org/10.1038/gim.2014.11>
- Malfait, F. (2018). Vascular aspects of the Ehlers-Danlos Syndromes. *Matrix Biol*, 71-72, 380-395. <https://doi.org/10.1016/j.matbio.2018.04.013>
- Malfait, F., Francomano, C., Byers, P., Belmont, J., Berglund, B., Black, J., Bloom, L., Bowen, J. M., Brady, A. F., Burrows, N. P., Castori, M., Cohen, H., Colombi, M., Demirdas, S., De Backer, J., De Paepe, A., Fournel-Gigleux, S., Frank, M., Ghali, N., . . . Tinkle, B. (2017). The 2017 international classification of the Ehlers-Danlos syndromes. *Am J Med Genet C Semin Med Genet*, 175(1), 8-26. <https://doi.org/10.1002/ajmg.c.31552>
- Mariath, L. M., Santin, J. T., Frantz, J. A., Doriqui, M. J. R., Kiszewski, A. E., & Schuler-Faccini, L. (2019). An overview of the genetic basis of epidermolysis bullosa in Brazil: discovery of novel and recurrent disease-causing variants. *Clin Genet*, 96(3), 189-198. <https://doi.org/10.1111/cge.13555>
- Miller, D. T., Lee, K., Chung, W. K., Gordon, A. S., Herman, G. E., Klein, T. E., Stewart, D. R., Amendola, L. M., Adelman, K., Bale, S. J., Gollob, M. H., Harrison, S. M., Hershberger, R. E., McKelvey, K., Richards, C. S., Vlangos, C. N., Watson, M. S., & Martin, C. L. (2021). ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG). *Genet Med*, 23(8), 1381-1390. <https://doi.org/10.1038/s41436-021-01172-3>
- Miller, D. T., Lee, K., Gordon, A. S., Amendola, L. M., Adelman, K., Bale, S. J., Chung, W. K., Gollob, M. H., Harrison, S. M., Herman, G. E., Hershberger, R. E., Klein, T. E., McKelvey, K., Richards, C. S., Vlangos, C. N., Stewart, D. R., Watson, M. S., & Martin, C. L. (2021). Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2021 update: a policy statement of the American College of Medical Genetics and Genomics (ACMG). *Genet Med*, 23(8), 1391-1398. <https://doi.org/10.1038/s41436-021-01171-4>
- Murrell, D. (2020, September 10). *Overview of the management of epidermolysis bullosa*. <https://www.uptodate.com/contents/overview-of-the-management-of-epidermolysis-bullosa>
- Musunuru, K., Hershberger Ray, E., Day Sharlene, M., Klindedinst, N. J., Landstrom Andrew, P., Parikh Victoria, N., Prakash, S., Semsarian, C., Sturm Amy, C., & null, n. (2020). Genetic Testing for Inherited Cardiovascular Diseases: A Scientific Statement From the American Heart Association. *Circulation: Genomic and Precision Medicine*, 13(4), e000067. <https://doi.org/10.1161/HCG.000000000000067>
- Nataatmadja, M., West, M., West, J., Summers, K., Walker, P., Nagata, M., & Watanabe, T. (2003). Abnormal extracellular matrix protein transport associated with increased apoptosis of vascular smooth muscle cells in marfan syndrome and bicuspid aortic valve thoracic aortic aneurysm. *Circulation*, 108 Suppl 1, Ii329-334. <https://doi.org/10.1161/01.cir.0000087660.82721.15>

Genetic Testing for Connective Tissue Disorders AHS – M2144

- Neptune, E. R., Frischmeyer, P. A., Arking, D. E., Myers, L., Bunton, T. E., Gayraud, B., Ramirez, F., Sakai, L. Y., & Dietz, H. C. (2003). Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. *Nat Genet*, 33(3), 407-411. <https://doi.org/10.1038/ng1116>
- NIH. (2016). *What are heritable disorders of connective tissue?* <https://www.niams.nih.gov/health-topics/heritable-disorders-connective-tissue>
- NIH. (2020). Epidermolysis bullosa simplex. <https://ghr.nlm.nih.gov/condition/epidermolysis-bullosa-simplex#genes>
- NORD. (2013). *Epidermolysis Bullosa*. <https://rarediseases.org/rare-diseases/epidermolysis-bullosa/>
- NORD. (2017). *Ehlers Danlos Syndromes*. Retrieved January 20 from <https://rarediseases.org/rare-diseases/ehlers-danlos-syndrome/>
- Overview of Cardiac Management in Marfan Syndrome*. (2015). The Marfan Foundation. <https://www.marfan.org/resource/fact-sheet/cardiac-management-marfan-syndrome#.XjCXtWhKiUk>
- Pauker, S., & Stoler, J. (2020, April 22). *Clinical manifestations and diagnosis of Ehlers-Danlos syndromes*. <https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-ehlers-danlos-syndromes>
- Pyeritz, R. E. (2012). Evaluation of the adolescent or adult with some features of Marfan syndrome. *Genet Med*, 14(1), 171-177. <https://doi.org/10.1038/gim.2011.48>
- Pyeritz, R. E. (2017). Etiology and pathogenesis of the Marfan syndrome: current understanding. *Ann Cardiothorac Surg*, 6(6), 595-598. <https://doi.org/10.21037/acs.2017.10.04>
- Radke, R. M., & Baumgartner, H. (2014). Diagnosis and treatment of Marfan syndrome: an update. *Heart*, 100(17), 1382-1391. <https://doi.org/10.1136/heartjnl-2013-304709>
- Ritelli, M., Rovati, C., Venturini, M., Chiarelli, N., Cinquina, V., Castori, M., & Colombi, M. (2020). Application of the 2017 criteria for vascular Ehlers-Danlos syndrome in 50 patients ascertained according to the Villefranche nosology. *Clin Genet*, 97(2), 287-295. <https://doi.org/10.1111/cge.13653>
- Ryan, T. D., Lucky, A. W., King, E. C., Huang, G., Towbin, J. A., & Jefferies, J. L. (2016). Ventricular dysfunction and aortic dilation in patients with recessive dystrophic epidermolysis bullosa. *Br J Dermatol*, 174(3), 671-673. <https://doi.org/10.1111/bjd.14168>
- Saunderson, R. B., Vekic, D. A., Mallitt, K., Mahon, C., Robertson, S. J., & Wargon, O. (2019). A retrospective cohort study evaluating the accuracy of clinical diagnosis compared with immunofluorescence and electron microscopy in children with inherited epidermolysis bullosa. *Br J Dermatol*, 180(5), 1258-1259. <https://doi.org/10.1111/bjd.17648>
- Seike, Y., Matsuda, H., Inoue, Y., Sasaki, H., Morisaki, H., Morisaki, T., & Kobayashi, J. (2020). The differences in surgical long-term outcomes between Marfan syndrome and Loeys-Dietz syndrome. *J Thorac Cardiovasc Surg*. <https://doi.org/10.1016/j.jtcvs.2020.07.089>
- Sellers, S. L., Milad, N., Chan, R., Mielnik, M., Jermilova, U., Huang, P. L., de Crom, R., Hirota, J. A., Hogg, J. C., Sandor, G. G., Van Breemen, C., Esfandiarei, M., Seidman, M. A., & Bernatchez, P. (2018). Inhibition of Marfan Syndrome Aortic Root Dilation by Losartan: Role of Angiotensin II Receptor Type 1-Independent Activation of Endothelial Function. *Am J Pathol*, 188(3), 574-585. <https://doi.org/10.1016/j.ajpath.2017.11.006>
- Shalhub, S., Byers, P. H., Hicks, K. L., Coleman, D. M., Davis, F. M., De Caridi, G., Weaver, K. N., Miller, E. M., Schermerhorn, M. L., Shean, K., Oderich, G., Ribeiro, M., Nishikawa, C., Charlton-Ouw, K., Behrendt, C. A., Debus, E. S., von Kodolitsch, Y., Zarkowsky, D., Powell, R. J., . . . Woo, K. (2020). A multi-institutional experience in vascular Ehlers-Danlos syndrome diagnosis. *J Vasc Surg*, 71(1), 149-157. <https://doi.org/10.1016/j.jvs.2019.04.487>
- Tinkle, B. T., & Saal, H. M. (2013). Health Supervision for Children With Marfan Syndrome. *Pediatrics*, 132(4), e1059. <https://doi.org/10.1542/peds.2013-2063>
- Wright, M., & Connolly, H. (2021, March 30). *Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders*. <https://www.uptodate.com/contents/genetics-clinical-features-and-diagnosis-of-marfan-syndrome-and-related-disorders>

Specialty Matched Consultant Advisory Panel review 3/2020

Medical Director review 3/2020

Genetic Testing for Connective Tissue Disorders AHS – M2144

Specialty Matched Consultant Advisory Panel review 3/2021

Medical Director review 3/2021

Policy Implementation/Update Information

- 1/1/2019 BCBSNC will provide coverage for genetic testing for marfan syndrome when it is determined to be medically necessary because criteria and guidelines are met. Medical Director review 1/1/2019. Policy noticed 1/1/2019 for effective date 4/1/2019. (jd)
- 5/14/19 Reviewed by Avalon 1st Quarter 2019 CAB. Minor revisions to Description and When Covered sections; no change to policy intent. Policy guidelines extensively revised. Referenced updated. Medical Director review 5/2019. (jd)
- 10/29/19 Wording in the Policy, When Covered, and/or Not Covered section(s) changed from Medical Necessity to Reimbursement language, where needed.
- 5/12/20 Policy title changed from “Marfan Syndrome” to “Genetic Testing for Connective Tissue Disorders. Reviewed by Avalon 1st Quarter 2020 CAB. Added items #3 and #4 to the When Covered section. Under the When Not Covered section, added “All others” to the not medically necessary statement. Added Related Policies section. Description, policy guidelines, and references updated. Specialty Matched Consultant Advisory Panel review 3/2020. Medical Director review 3/2020. (jd)
- 4/20/21 Specialty Matched Consultant Advisory Panel review 3/2021. Medical Director review 3/2021. (jd)
- 5/4/21 Reviewed by Avalon 1st Quarter 2021 CAB. Added the following statement to item 1 under the When Covered section: “the individual needs to consult cardiology specialist prior to genetic testing” for clarity; removed the following from item 2 “If FBN1 mutation testing is negative”; item 3 reworded about genetic testing (COL3A1 and COL1A1) for vascular Ehlers-Danlos syndrome (vEDS); reworded item 4 for clarity. Note 3 updated. Added 2nd statement to When Not Covered section: “Reimbursement is not allowed for genetic testing to confirm or establish a diagnosis of hypermobile Ehlers-Danlos syndrome (hEDS) in individuals with characteristics of hEDS (see Note 5).; and added Note 5. Description section, policy guidelines and references updated. Medical Director review 4/2021. (jd)
- 5/17/22 Reviewed by Avalon 1st Quarter 2022 CAB. Updated policy guidelines; adding Table of Terminology and references. Medical Director review 4/2022. (jd)

Medical policy is not an authorization, certification, explanation of benefits or a contract. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the group contract and subscriber certificate that is in effect at the time services are rendered. This document is solely provided for informational purposes only and is based on research of current medical literature and review of common medical practices in the treatment and diagnosis of disease. Medical practices and knowledge are constantly changing and BCBSNC reserves the right to review and revise its medical policies periodically.